Cargando…

Efficacy of Low-Dose Trimethoprim/Sulfamethoxazole for the Treatment of Pneumocystis jirovecii Pneumonia in Deceased Donor Kidney Recipients

BACKGROUND: Trimethoprim/sulfamethoxazole (TMP-SMX) is considered the first-choice treatment for Pneumocystis jirovecii pneumonia (PJP) in recipients of solid organ transplantation. However, this treatment is associated with various severe adverse events that might not be tolerable for some renal tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ji, Jianlei, Wang, Qinghai, Huang, Tao, Wang, Ziyu, He, Pingli, Guo, Chen, Xu, Weijia, Cao, Yanwei, Dong, Zhen, Wang, Hongyang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628180/ https://www.ncbi.nlm.nih.gov/pubmed/34853519 http://dx.doi.org/10.2147/IDR.S339622

Ejemplares similares

A Case of Pneumonia Caused by Pneumocystis jirovecii Resistant to Trimethoprim-Sulfamethoxazole
por: Lee, Sang Min, et al.
Publicado: (2015)

Lifelong Prophylaxis With Trimethoprim-Sulfamethoxazole for Prevention of Outbreak of Pneumocystis jirovecii Pneumonia in Kidney Transplant Recipients
por: Goto, Norihiko, et al.
Publicado: (2017)

Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation
por: Prasad, G. V. Ramesh, et al.
Publicado: (2019)

Trimethoprim-Sulfamethoxazole (Bactrim) Dose Optimization in Pneumocystis jirovecii Pneumonia (PCP) Management: A Systematic Review
por: Haseeb, Abdul, et al.
Publicado: (2022)

Treatment With Reduced-Dose Trimethoprim-Sulfamethoxazole Is Effective in Mild to Moderate Pneumocystis jirovecii Pneumonia in Patients With Hematologic Malignancies
por: Hammarström, Helena, et al.
Publicado: (2022)

Impact of an Intravenous Trimethoprim/Sulfamethoxazole Shortage on Treatment Outcomes Among HIV-Infected Patients with Pneumocystis jirovecii Pneumonia
por: Dilworth, Thomas J., et al.
Publicado: (2014)

401. Pneumocystis jirovecii Pneumonia in Renal Transplant Recipients After a 6-Month Trimethoprim–Sulfamethoxazole Prophylaxis: A Case–Control Study
por: Park, Se Yoon, et al.
Publicado: (2018)

Treatment of Pneumocystis jirovecii pneumonia in non-human immunodeficiency virus-infected patients using a combination of trimethoprim-sulfamethoxazole and caspofungin
por: Wu, Huan-Huan, et al.
Publicado: (2022)

Time to trimethoprim/sulfamethoxazole initiation among patients with rheumatic disease complicated by Pneumocystis jirovecii pneumonia: impact on 90-day mortality
por: Song, Siyang, et al.
Publicado: (2022)

Multicenter Study of Trimethoprim/Sulfamethoxazole-Related Hepatotoxicity: Incidence and Associated Factors among HIV-Infected Patients Treated for Pneumocystis jirovecii Pneumonia
por: Yang, Jen-Jia, et al.
Publicado: (2014)

Combination therapy with trimethoprim-sulfamethoxazole and caspofungin in a case of severe pneumocystis pneumonia
por: Koshy, Robin, et al.
Publicado: (2019)

Low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (LOW-TMP): protocol for a phase III randomised, placebo-controlled, dose-comparison trial
por: Sohani, Zahra N., et al.
Publicado: (2022)

807. Trimethoprim/Sulfamethoxazole for Pneumocystis jirovecii pneumonia prophylaxis in B-cell lymphoma: A multicenter randomized double-blinded placebo-controlled trial
por: Angsutararux, Taksaon, et al.
Publicado: (2023)

Impact of Increased Duration of Trimethoprim-Sulfamethoxazole Prophylaxis for Pneumocystis Pneumonia After Renal Transplant
por: Chapman, Fiona A., et al.
Publicado: (2019)

Prolonged and recurrent hypoglycemia induced by trimethoprim-sulfamethoxazole in a Hodgkin lymphoma patient with Pneumocystis carinii pneumonia
por: Wang, Bing-Jie, et al.
Publicado: (2021)

A Pilot Study of Echinocandin Combination with Trimethoprim/Sulfamethoxazole and Clindamycin for the Treatment of AIDS Patients with Pneumocystis Pneumonia
por: Wang, Mengyan, et al.
Publicado: (2019)

Therapeutic Potential of Caspofungin Combined with Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia: A Pilot Study in Mice
por: Lobo, Maria Luísa, et al.
Publicado: (2013)

Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids
por: Park, Jun Won, et al.
Publicado: (2018)

Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole used as First-Line Treatment for Pneumocystis jirovecii Pneumonia
por: Kim, Tark, et al.
Publicado: (2018)

A retrospective study of patients with systemic lupus erythematosus combined with Pneumocystis jiroveci pneumonia treated with caspofungin and trimethoprim/sulfamethoxazole
por: Wang, Zhi-Guo, et al.
Publicado: (2019)

145. the Efficacy and Safety of Low Dose Trimethoprim-sulfamethoxazole for the Treatment of Pneumocystis Pneumonia: A Systematic Review and Meta-analysis
por: Tritle, Brandon, et al.
Publicado: (2020)

Preliminary Study on the Combination Effect of Clindamycin and Low Dose Trimethoprim-Sulfamethoxazole on Severe Pneumocystis Pneumonia After Renal Transplantation
por: Gu, Zhun-Yong, et al.
Publicado: (2022)

Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim–sulfamethoxazole: lessons from an observational cohort study
por: Creemers-Schild, Dina, et al.
Publicado: (2015)

Hypercalcaemia preceding diagnosis of Pneumocystis jirovecii pneumonia in renal transplant recipients
por: Ling, Jonathan, et al.
Publicado: (2017)

Risk factors for Pneumocystis jirovecii pneumonia (PJP) in kidney transplantation recipients
por: Lee, Su Hwan, et al.
Publicado: (2017)

Pneumocystis jirovecii pneumonia in liver transplant recipients in an era of routine prophylaxis
por: Andreasen, Philip B., et al.
Publicado: (2021)

Correspondence Regarding the Article Titled “Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole Used as First-Line Treatment for Pneumocystis jirovecii Pneumonia”
por: Lee, Chang-Hoon
Publicado: (2018)

Pneumocystis jirovecii pneumonia in developing countries
por: De Armas Rodríguez, Y., et al.
Publicado: (2011)

Sulfamethoxazole-Trimethoprim and Hyperkalemia in an Infant
por: Hudzik, Samantha A., et al.
Publicado: (2020)

No Statistically Apparent Difference in Antifungal Effectiveness Observed Among Trimethoprim/Sulfamethoxazole Plus Clindamycin or Caspofungin, and Trimethoprim/Sulfamethoxazole Monotherapy in HIV-Infected Patients with Moderate to Severe Pneumocystis Pneumonia: Results of an Observational Multicenter Cohort Study
por: Huang, Yinqiu, et al.
Publicado: (2022)

Clinical descriptive analysis of severe Pneumocystis jirovecii pneumonia in renal transplantation recipients
por: Xie, Dan, et al.
Publicado: (2021)

Distinct Clinical and Laboratory Patterns of Pneumocystis jirovecii Pneumonia in Renal Transplant Recipients
por: Meyer, Andreas M. J., et al.
Publicado: (2021)

1592. Safety of Oral Trimethoprim/Sulfamethoxazole Prophylaxis in Renal Transplant Recipients
por: Horvat, Courtney, et al.
Publicado: (2018)

Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids—clinical implication of primary prophylaxis using trimethoprim–sulfamethoxazole
por: Park, Jun Won, et al.
Publicado: (2019)

Reply: Correspondence Regarding the Article Titled “Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole Used as First-Line Treatment for Pneumocystis jirovecii Pneumonia”
por: Kim, Tark, et al.
Publicado: (2018)

Trimethoprim-sulfamethoxazole induced eosinophilic pneumonia: A case report
por: Mochizuka, Yasutaka, et al.
Publicado: (2022)

1491. Standard- vs. High-dose Trimethoprim-Sulfamethoxazole for Stenotrophomonas maltophilia pneumonia
por: Hall, Brenton C, et al.
Publicado: (2020)

The impact of trimethoprim-sulfamethoxazole as Pneumocystis jiroveci pneumonia prophylaxis on the occurrence of asymptomatic bacteriuria and urinary tract infections among renal allograft recipients: a retrospective before-after study
por: Singh, Ramandeep, et al.
Publicado: (2016)

A Case of a Pneumocystis Pneumonia Twenty-four Years After Living Kidney Transplantation Due to Withdrawal of Sulfamethoxazole/Trimethoprim Prophylaxis
por: Kono, Momoko, et al.
Publicado: (2018)

Efficacy of Trimethoprim–Sulfamethoxazole in Combination with an Echinocandin as a First-Line Treatment Option for Pneumocystis Pneumonia: A Systematic Review and Meta-Analysis
por: Kato, Hideo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gebj4cimj0ao8ph87l823c4gmn